Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and reporting period: The filing covers the fiscal third quarter and nine months ended June 30, 2021; it was filed August 12, 2021. Citius is a development-stage specialty pharmaceutical company focused on Mino-Lok, Mino-Wrap, Halo-Lido, and, through its 75%-owned subsidiary NoveCite, a stem-cell therapy for acute respiratory distress syndrome (ARDS). The company reported no revenue in either 2021 or the comparable 2020 periods.
Key financial metrics
| Metric | Three months ended June 30, 2021 | Nine months ended June 30, 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.20 million | $9.95 million |
| General and administrative expense | $3.41 million | $7.39 million |
| Stock-based compensation expense | $0.37 million | $0.99 million |
| Total operating expenses | $5.98 million | $18.33 million |
| Operating loss | $5.98 million | $18.33 million |
| Net loss | $5.82 million | $18.09 million |
| Net loss applicable to common stockholders | $7.27 million | $19.54 million |
| Loss per common share, basic and diluted | $0.05 | $0.20 |
| Net cash used in operating activities | Nine months: $18.66 million |
At June 30, 2021, cash and cash equivalents were $115.66 million, working capital was approximately $113 million, and total liabilities were $9.31 million. Current liabilities were $3.60 million. Related-party notes were repaid in June; the $164,583 PPP loan was forgiven after quarter-end. The company reported no revenue, so operating margins are not meaningful.
Changes versus comparable periods
- Quarterly net loss increased by $1.14 million from $4.68 million in 2020. Higher G&A and stock compensation more than offset lower R&D expense.
- Nine-month net loss increased by $4.67 million from $13.43 million. R&D rose $2.62 million and G&A rose $1.70 million.
- Nine-month R&D included a $5 million license payment for NoveCite’s ARDS technology. ARDS-related R&D was $6.29 million versus $0.76 million in 2020; Mino-Lok and Halo-Lido spending declined, principally due to lower manufacturing and registration-batch costs.
- Cash increased from $13.86 million at September 30, 2020, mainly from equity financings and warrant exercises. Financing activities provided $120.47 million during the nine-month period.
- Shares outstanding increased from 55.58 million at September 30, 2020 to 145.98 million at June 30, 2021. The company also reported 40.23 million outstanding warrants, in addition to options and shares reserved for future grants.
Outlook, commentary, and risks
- Management estimated available cash would fund operations through March 2023. The company expects further R&D spending in fiscal 2021, with efforts focused on the Mino-Lok Phase 3 trial, Halo-Lido, ARDS, and Mino-Wrap.
- The company has incurred operating losses since inception and depends on external financing and eventual product approvals and sales. Management cautioned that operations beyond March 2023 may require additional capital; financing, partnerships, regulatory approvals, and commercial success are not assured.
- In April 2021, the company extended certain warrants by three years and recorded a $1.45 million deemed dividend. This increased the loss applicable to common stockholders but not reported net loss.
- Novellus, the NoveCite licensor, was acquired by Brooklyn ImmunoTherapeutics in July 2021. The related stock subscription agreement was amended, replacing anti-dilution protection with a right of first refusal. The NoveCite license also provides for up to $51 million in development and regulatory milestone payments and royalties if products are commercialized.
- The PPP loan was formally forgiven July 28, 2021. The company reported no legal proceedings, no material change in risk factors from its latest Form 10-K, and effective disclosure controls as of June 30, 2021.
Important facts for investors to verify
- Progress, timing, and results of the Mino-Lok Phase 3 trial and the regulatory path for each product candidate.
- Whether the stated cash runway through March 2023 remains realistic as clinical and development spending changes.
- Potential dilution from 40.23 million warrants, outstanding options, and shares available for future grants.
- Material terms and future obligations under the NoveCite license, including milestone payments, royalties, and the amended right of first refusal.
- That the $1.45 million warrant-extension deemed dividend affects common-stockholder loss, while net loss for the quarter was $5.82 million.